Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 2/20 | 0.45 |
| ▸ | PRCP | P42785 | 5/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31062461 | 0.89 | PRCP (0.56) | GID4PRCPRECQLGAAHTR2A | |
| SCHEMBL327054 | 0.89 | PRCP (0.56) | GID4PRCPRECQLGAAHTR2A | |
| Hydrochloric Acid SCHEMBL2771890 | 0.88 | PRCP (0.54) | GID4PRCPRECQLGAAHTR2A | |
| SCHEMBL4766983 | 0.78 | ALDH1A1 (0.40) | GID4PRCP | |
| SCHEMBL13091446 | 0.77 | PRCP (0.49) | GID4PRCPRECQLGAAHTR2A | |
| SCHEMBL5691750 | 0.73 | PRCP (0.35) | PRCPIDO1GAAOPRM1 | |
| SCHEMBL28409392 | 0.73 | PRCP (0.46) | PRCPRECQLGAA | |
| SCHEMBL8813918 | 0.72 | GID4 (0.49) | GID4PRCPRECQLGAAHTR2A | |
| SCHEMBL28302626 | 0.72 | GID4 (0.49) | GID4PRCPRECQLGAAHTR2A | |
| Hydrochloric Acid SCHEMBL28262412 | 0.71 | GAA (0.47) | PRCPRECQLIDO1GAAOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | IGF1R, INSR, GPR119 | GID4 275/4885PRCP 3452/4885RECQL 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.